Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hodgkin's disease.

V Diehl1, A Josting

  • 1First Department of Internal Medicine, University Hospital Cologne, Germany.

Cancer Journal (Sudbury, Mass.)
|May 10, 2000
PubMed
Summary
This summary is machine-generated.

Hodgkin's disease (HD) is a monoclonal B-cell disorder. Treatment is shifting from radiation to chemotherapy and involved field irradiation, improving outcomes in advanced and relapsed stages.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improvement in the outcome of invasive fusariosis in the last decade.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2013
Same author

Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis.

Annals of oncology : official journal of the European Society for Medical Oncology·2010
Same author

Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2008
Same author

[Secondary malignancies after successful primary treatment of malignant Hodgkin's lymphoma].

Der Pathologe·2005
Same author

BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease - results of the German Hodgkin Study Group.

Leukemia & lymphoma·2005
Same author

Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG).

Annals of oncology : official journal of the European Society for Medical Oncology·2005
Same journal

Present and Emerging Strategies for Disease Assessment in Hodgkin Lymphoma.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Nodular Lymphocyte-predominant Hodgkin Lymphoma: Incidence, Pathogenesis, Management.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Management of Classic Hodgkin Lymphoma in Special Clinical Situations.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Older Patients With Hodgkin Lymphoma: A Contemporary Review.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Adolescent and Young Adult Patients With Classical Hodgkin Lymphoma: A Review as a Case Study in AYA Cancer Care.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Hodgkin Lymphoma: Management of Patients Who Fail Primary Therapy.

Cancer journal (Sudbury, Mass.)·2026
See all related articles

Area of Science:

  • Oncology
  • Hematology
  • Immunology

Background:

  • Hodgkin's disease (HD) is increasingly recognized as a monoclonal B-cell disorder.
  • Traditional treatments for HD, like extended field irradiation, are being re-evaluated due to long-term side effects such as secondary solid tumors.
  • Treatment strategies for HD are evolving to improve efficacy and reduce toxicity.

Purpose of the Study:

  • To summarize the evolving treatment landscape of Hodgkin's disease.
  • To highlight the shift in therapeutic approaches for different stages of HD.
  • To present recent advancements in managing advanced and relapsed Hodgkin's disease.

Main Methods:

  • Review of current treatment standards and emerging therapeutic strategies for Hodgkin's disease.

Related Experiment Videos

  • Analysis of changes in radiotherapy and chemotherapy protocols based on long-term outcome data.
  • Inclusion of findings from recent phase III studies on novel treatment regimens.

    • Main Results:

    • In early-stage HD, involved field irradiation combined with mild chemotherapy is replacing extended field irradiation.
    • For advanced-stage HD, a dose-intensified regimen (BEACOPP) has significantly improved prognosis compared to previous polychemotherapy.
    • High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) shows promise in improving relapse-free survival for relapsed HD patients.

    Conclusions:

    • Hodgkin's disease treatment is transitioning towards less toxic and more effective modalities.
    • The adoption of involved field irradiation and dose-intensified chemotherapy regimens marks significant progress.
    • Autologous stem cell transplantation is a key advancement for managing relapsed Hodgkin's disease.